Total Current Liabilities - CASI Pharmaceuticals Inc (NASDAQ:CASI) - Alpha Spread
C

CASI Pharmaceuticals Inc
NASDAQ:CASI

Watchlist Manager
CASI Pharmaceuticals Inc
NASDAQ:CASI
Watchlist
Price: 6.54 USD -3.25% Market Closed
Market Cap: 87.6m USD
Have any thoughts about
CASI Pharmaceuticals Inc?
Write Note

CASI Pharmaceuticals Inc
Total Current Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CASI Pharmaceuticals Inc
Total Current Liabilities Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors

Company Total Current Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
C
CASI Pharmaceuticals Inc
NASDAQ:CASI
Total Current Liabilities
$16.7m
CAGR 3-Years
28%
CAGR 5-Years
34%
CAGR 10-Years
39%
Abbvie Inc
NYSE:ABBV
Total Current Liabilities
$41.9B
CAGR 3-Years
13%
CAGR 5-Years
20%
CAGR 10-Years
21%
Gilead Sciences Inc
NASDAQ:GILD
Total Current Liabilities
$10.8B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
6%
Amgen Inc
NASDAQ:AMGN
Total Current Liabilities
$21.5B
CAGR 3-Years
14%
CAGR 5-Years
15%
CAGR 10-Years
11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Current Liabilities
$3.5B
CAGR 3-Years
25%
CAGR 5-Years
23%
CAGR 10-Years
26%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Current Liabilities
$3.5B
CAGR 3-Years
-2%
CAGR 5-Years
15%
CAGR 10-Years
26%

See Also

What is CASI Pharmaceuticals Inc's Total Current Liabilities?
Total Current Liabilities
16.7m USD

Based on the financial report for Dec 31, 2023, CASI Pharmaceuticals Inc's Total Current Liabilities amounts to 16.7m USD.

What is CASI Pharmaceuticals Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
39%

Over the last year, the Total Current Liabilities growth was -2%. The average annual Total Current Liabilities growth rates for CASI Pharmaceuticals Inc have been 28% over the past three years , 34% over the past five years , and 39% over the past ten years .

Back to Top